GRALGRAIL, Inc.

$2B

Q3 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$29M+38.3% YoY

Gross Profit

-$22M-77.6% margin

Operating Income

-$184M-640.5% margin

Net Income

-$126M-438.7% margin

EPS (Diluted)

$-3.94

QoQ Revenue Growth

-10.4%

Cash Flow

Operating Cash Flow

-$105M

Free Cash Flow

-$106M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$3.1B

Total Liabilities

$530M

Stockholders' Equity

$2.6B

Cash & Equivalents

$854M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$21M	+38.3%
Gross Profit	-$22M	-$27M	+17.9%
Operating Income	-$184M	-$912M	+79.9%
Net Income	-$126M	-$891M	+85.9%

GRAL Q3 2024 Earnings — GRAIL, Inc. Revenue & Financial Results | Market Cap Arena